Effects of sitagliptin on on BNP, NT-proBNP, cGMP, aldosterone and LVMI in patients with type 2 diabetes and stable chronic heart failure

Trial Profile

Effects of sitagliptin on on BNP, NT-proBNP, cGMP, aldosterone and LVMI in patients with type 2 diabetes and stable chronic heart failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2011

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Chronic heart failure; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Sep 2011 New trial record
    • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top